The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC).
 
Corbin Eule
No Relationships to Disclose
 
Junxiao Hu
No Relationships to Disclose
 
Sulaiman Al-Saadi
No Relationships to Disclose
 
Katharine Collier
Research Funding - Conquer Cancer Foundation
 
Patrick James Boland
No Relationships to Disclose
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Vivek Narayan
Honoraria - Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Exelixis; Janssen Oncology; Merck; Myovant Sciences; Pfizer/EMD Serono; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Tmunity Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Dominick Bosse
Honoraria - Amgen; AstraZeneca; BMS; Eisai; Ipsen; Janssen; Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca Canada; Bayer; Bristol-Myers Squibb; Ipsen; Merck; Merck; Pfizer
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Tracy L Rose
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GeneCentric (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Elaine T. Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Arrowhead Pharmaceuticals (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Decibel Therapeutics